| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2029-03-07 |
| Par Value | 2000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 1750.00 |
| Coupon | 3.4 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 1750 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Merck & Co Inc corporate note has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million USD and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
Merck & Co Inc, founded in 1891 and headquartered in Kenilworth, New Jersey, is a leading global healthcare company dedicated to the research, development, manufacturing, and marketing of prescription medicines, vaccines, biologic therapies, and animal health products. Notable products include the cancer immunotherapy Keytruda, the HPV vaccine Gardasil, and various treatments for cardiovascular and infectious diseases.